• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fsd Pharma Inc Cl B (NQ: HUGE )

    0.1432 -0.0016 (-1.10%)
    Streaming Delayed Price Updated: 1:09 PM EDT, Jul 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 225,732
    Open 0.1400
    Bid (Size) 0.1416 (1)
    Ask (Size) 0.1445 (37)
    Prev. Close 0.1448
    Today's Range 0.1380 - 0.1447
    52wk Range 0.1300 - 1.680
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR
    Via Investor Brand Network
    BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness
    Via Investor Brand Network

    Performance

    YTD
    -84.09%
    -84.09%
    1 Month
    -40.58%
    -40.58%
    3 Month
    -76.53%
    -76.53%
    6 Month
    -85.82%
    -85.82%
    1 Year
    -88.17%
    -88.17%

    More News

    Read More
    FSD Pharma provides Corporate Update
    Via ACCESSWIRE
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Awarded Final Judgment, Confirmation of $3M-Plus Arbitration Award
    Via Investor Brand Network
    HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024
    Via InvestorPlace
    FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
    Via ACCESSWIRE
    BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
    Via Investor Brand Network
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
    Via Investor Brand Network
    FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
    Via ACCESSWIRE
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Signs Option Agreement with USC to Exclusively Evaluate Novel Technology for Commercialization
    Via Investor Brand Network
    FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
    Via ACCESSWIRE
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces IRB Approval for Acute Alcohol Intoxication Study
    Via Investor Brand Network
    FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
    Via ACCESSWIRE
    InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Wins Petition, Awards for Damages and Fees
    Via Investor Brand Network
    FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
    Via ACCESSWIRE
    BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
    Via Investor Brand Network
    MiningNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
    Via Investor Brand Network
    BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency
    Via Investor Brand Network
    FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
    Via ACCESSWIRE
    FSD Pharma Provides Corporate Update
    Via ACCESSWIRE
    FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
    Via ACCESSWIRE
    TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
    Via Investor Brand Network
    FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
    Via ACCESSWIRE
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
    Via Investor Brand Network
    FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.